Tacrolimus is a drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.
Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration.
Bristol-Myers Squibb Company announced today that 14 abstracts on the Company's research in liver disease have been accepted for presentation at The International Liver CongressTM 2013, the 48th annual meeting of the European Association for the Study of the Liver, in Amsterdam, April 24 - 28.
Human diseases caused by misfolded proteins known as prions are some of most rare yet terrifying on the planet—incurable with disturbing symptoms that include dementia, personality shifts, hallucinations and coordination problems.
Novartis announced today that the US Food and Drug Administration (FDA) has approved Zortress (everolimus) for the prophylaxis of organ rejection in adult patients receiving a liver transplant.
Pfizer Inc. said today that the United States District Court for the District of Delaware ruled that Pfizer's patent covering a method for using sirolimus, the active ingredient in RAPAMUNE®, for the inhibition of organ transplant rejection is valid and infringed.
Breastfeeding mothers taking tacrolimus do not pass the immunosuppressant on to their babies when breastfeeding, study results show.
Women taking the immunosuppressant tacrolimus can rest assured that breast feeding will not elevate their babies' exposure to the drug, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).
Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its Thermo Scientific QMS Everolimus Assay Kit has been CE marked for sale in the European Union for a third application, namely liver transplants.
An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3 trial at the American Society of Hematology annual meeting.
The University of Cincinnati will lead a $5.2 million national trial studying removal of both corticosteroids and common immunosuppression treatments from the post-transplant drug regimen for kidney transplant patients.
A new substance class for the treatment of multiple sclerosis and other neurodegenerative diseases now promises increased efficacy paired with fewer side effects. To achieve this, a team of scientists under the leadership of Prof. Gunter Fischer and Dr. Frank Striggow have combined two already approved pharmaceutical substances with each other using a chemical linker structure.
Myasthenia gravis (MG) is an autoimmune disease that produces weakness and fatiguability of muscles. It affects between 1 and 7 people per 10,000, according to the best statistics.
Genetic study results show that long-term kidney transplant rejection risk may be increased if the organ donor has a variant form of the multidrug resistance 1 gene.
A new study at the University of Cincinnati seeks to end the questions over generic-vs.-brand for a common immunosuppressive drug for transplant patients, tacrolimus.
Research shows that even partially matched bone marrow transplants are able to eliminate sickle cell disease in some patients with sickle cell anemia.
Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for tacrolimus extended release capsules for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver transplant recipients.
Sirolimus, whether given at the time of liver transplantation or after, is associated with poorer outcomes in patients with hepatitis C virus infection compared with those who do not take the immunosuppressant, shows a US study.
Switching from calcineurin inhibitors to a sirolimus-containing immunosuppression regimen may help reduce the incidence of secondary skin cancer after kidney transplantation, suggests research published in TheNew England Journal of Medicine.
Kidney transplant patients vaccinated against Streptococcus pneumoniae appear to be protected against pneumococcal infection for at least 15 months, research shows.
An HIV drug that redirects immune cell traffic significantly reduces the incidence of a dangerous complication that often follows bone marrow transplants for blood cancer patients, according to research from the Perelman School of Medicine at the University of Pennsylvania that will be published today in the New England Journal of Medicine.